Kura Oncology is a clinically focused biotech company with its first proprietary product on the market, which reported significant losses amid rising revenue in the current reporting quarter—the classic scenario for a “highly speculative” stock. Loss Situation The net loss in Q2 2026 was $68.3 million, compared to $66.1 million in the same quarter of the previous year—so despite rising revenue, the loss actually widened slightly. This is due to high investments: research and development expenses totaled $61.9 million, while sales and administrative expenses amounted to $31.8 million, partly due to the expansion of the sales team for the product launch. For fiscal year 2025, the company reported an annual loss of $278.7 million (EPS: -$3.18). The loss per share in Q2 2026 was -$0.77, which was better than analysts’ estimate of -$0.88.
